Business UpdateMay 14, 2026, 04:07 PM
SpyGlass Pharma Reports Positive BIM-IOL Data; $251M Cash to Fund Ops thru 2028
AI Summary
SpyGlass Pharma reported positive topline 12-month data from its BIM-IOL System Phase 1/2 trial, showing 98% of participants were free from IOP-lowering topical eye drops and a 34% mean IOP reduction. The company's registrational Phase 3 trials for the BIM-IOL System are on track for enrollment completion in 2027, and the first-in-human trial for BIM-DRS is expected to start in the second half of 2026. Financially, SpyGlass Pharma held $251.0 million in cash, cash equivalents, and short-term investments as of March 31, 2026, which is projected to fund operations through 2028. The company reported a net loss of $13.8 million for the first quarter of 2026.
Key Highlights
- BIM-IOL System Phase 1/2 trial showed 98% of participants eliminated IOP-lowering eye drops.
- BIM-IOL System Phase 1/2 trial demonstrated 34% mean intraocular pressure (IOP) reduction.
- Registrational Phase 3 trials for BIM-IOL System remain on track for enrollment completion in 2027.
- Bimatoprost-Drug Ring System (BIM-DRS) first-in-human trial is set to begin in H2 2026.
- Cash, cash equivalents, and short-term investments totaled $251.0 million as of March 31, 2026.
- Cash is expected to fund planned operations through 2028.
- Net Loss for Q1 2026 was $13.8 million, or ($0.69) per share.
- R&D expenses increased to $8.5 million in Q1 2026 from $6.1 million in Q1 2025.